Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. (NASDAQ: MDCX) has filed Offering Circular Supplement No. 8 under Rule 253(g)(2), updating its April 10, 2025 Offering Circular. The filing attaches the company’s June 30, 2025 Current Report, which discloses a definitive agreement to acquire Antev Ltd., a clinical-stage biotech developing the GnRH antagonist Teverelix for prostate-related indications.
Transaction terms: Medicus will issue 2,666,600 new common shares (≈ 17 % of pro-forma shares outstanding) to Antev securityholders. Shares will be subject to a 36-month staggered lock-up and voting proxy in favour of Medicus management. Antev holders may receive up to US$65 million in milestone payments tied to future FDA Phase 2 and NDA approvals. Closing is targeted before end-August 2025, pending shareholder and regulatory consents.
Capital structure context: The company already has 1,490,000 common shares reserved for warrant exercises (strike $4.64, expiry Nov 15 2029). As of June 27 shares traded at $2.90 and public warrants at $0.95. The filing reiterates Medicus’ “emerging growth company” status and directs investors to existing risk disclosures.
Strategic rationale: The acquisition adds a late-preclinical/early-clinical asset targeting sizable prostate-cancer and BPH markets. Management highlights potential first-in-class positioning and cardiovascular safety advantages. However, the deal entails immediate dilution and substantial contingent consideration, and its completion is uncertain.
Medicus Pharma has filed a 253G2 offering circular supplement announcing key executive changes and warrant details. The company is offering 1,490,000 common shares issuable upon warrant exercise, with Public Warrants having an exercise price of $4.64 and expiration date of November 15, 2029.
Key highlights:
- Appointed Andrew Smith (57) as Chief Operating Officer, effective June 30, 2025
- Smith brings 30+ years experience in asset management and financial operations
- Employment package includes $325,000 annual base salary and 100,000 stock options at $2.60 strike price, vesting quarterly over 5 years
- Trading on Nasdaq Capital Market under symbols MDCX (shares) and MDCXW (warrants)
- Last reported share price: $2.49; warrant price: $0.80 (as of June 20, 2025)
The company maintains emerging growth company status, qualifying for reduced public company disclosure requirements.
Medicus Pharma announced the appointment of Andrew Smith (57) as Chief Operating Officer, effective June 30, 2025. The company filed a prospectus supplement regarding up to 3,710,000 common shares trading on Nasdaq under symbol MDCX at a last reported price of $2.49 on June 20, 2025.
Key details of Smith's appointment:
- Brings 30+ years of experience in asset management and financial operations
- Annual base salary: $325,000
- Stock option grant: 100,000 shares at $2.60 strike price, vesting quarterly over 5 years
- Previous roles include CEO of SR Asset Management and senior positions at Aberdeen Asset Management
- Holds Executive MBA from INSEAD and HND in Accounting from Glasgow College of Commerce
The company is classified as an emerging growth company, eligible for reduced public company disclosure requirements. The filing includes standard risk disclaimers and confirms no reportable related-party transactions with Smith.
Medicus Pharma announced the appointment of Andrew Smith (57) as Chief Operating Officer, effective June 30, 2025. The filing details a prospectus supplement covering 2,260,000 common shares issuable upon warrant exercise at $4.64 per share, expiring November 15, 2029.
Key appointment details:
- Annual base salary: $325,000
- Stock option grant: 100,000 shares at $2.60 strike price, vesting quarterly over 5 years
- Extensive experience: Over 30 years in asset management and financial operations
- Previous roles: CEO of SR Asset Management, COO at Aberdeen Asset Management
Trading information: As of June 20, 2025, MDCX shares traded at $2.49 and warrants (MDCXW) at $0.80 on Nasdaq Capital Market. The company is classified as an emerging growth company under SEC rules.
Medicus Pharma has filed a prospectus supplement (424B3) related to 1,115,500 common shares issuable upon warrant exercise. The company has appointed Andrew Smith as Chief Operating Officer, effective June 30, 2025.
Key details of the filing include:
- Public Warrants are exercisable at $4.64 with expiration on November 15, 2029
- Current trading prices as of June 20, 2025: Common shares at $2.49, Warrants at $0.80
- Smith's compensation package includes $325,000 annual base salary and 100,000 stock options at $2.60 strike price, vesting quarterly over 5 years
Smith brings over 30 years of experience, previously serving as CEO of SR Asset Management and holding leadership positions at Aberdeen Asset Management. The company is listed on Nasdaq Capital Market under symbols MDCX (shares) and MDCXW (warrants) and qualifies as an emerging growth company.
Medicus Pharma Ltd. has announced its Annual General and Special Meeting scheduled for July 22, 2025, at 10:00 AM ET in Toronto. Key agenda items include:
- Review of audited financial statements for 2023-2024
- Appointment of KPMG LLP as auditors
- Election of directors
- Amendment to increase shareholder meeting quorum requirements
- Approval of share issuance under Nasdaq Rule 5635(d) related to Standby Equity Purchase Agreement with YA II PN, Ltd.
- Special resolution for articles of incorporation amendment
The record date is set for June 2, 2025. Shareholders must submit proxies by July 18, 2025, 10:00 AM ET. The company, as an emerging growth company under JOBS Act, benefits from reduced reporting requirements and is not required to conduct advisory votes on executive compensation. The filing includes comprehensive information about corporate governance, executive compensation, and director nominations.
Medicus Pharma (NASDAQ: MDCX) has appointed Andrew Smith as Chief Operating Officer, effective June 30, 2025. Smith, 57, brings over three decades of experience in asset management and financial operations to the emerging growth company.
Key appointment details:
- Base salary: $325,000 annually
- Stock compensation: 100,000 options at $2.60 strike price, vesting quarterly over 5 years
- Prior experience includes CEO roles at SR Asset Management and leadership positions at Aberdeen Asset Management
- Educational background: Executive MBA from INSEAD and HND in Accounting from Glasgow College of Commerce
Smith initially joined as a consultant on May 27, 2025, and currently serves on the board of HazelTree Fund Services while advising Code Registry. The appointment involves no reportable related-party transactions or family relationships with other executives.